PI3K/AKT/PTEN pathway as a target for Crohn's disease therapy (Review)

International Journal of Molecular Medicine

Volumn 35, Issue 1, 2015, Pages 10-16

  Tokuhira, Nana ^a   Kitagishi, Yasuko ^a   Suzuki, Miho ^a   Minami, Akari ^a   Nakanishi, Atsuko ^a   Ono, Yuna ^a   Kobayashi, Keiko ^a   Matsuda, Satoru ^a   Ogura, Yasunori ^a  

^a NARA WOMEN'S UNIVERSITY   (Japan)

Author keywords

AKT; Crohn's disease; Inflammation; Mammalian target of rapamycin; Nucleotide binding oligomerization domain containing protein 2; Phosphatase and tensin homolog; Phosphatidylinositol 3 kinase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CURCUMIN; GUANOSINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYUNSATURATED FATTY ACID; PROTEIN KINASE B; WORTMANNIN; ENZYME INHIBITOR; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; CELL AGING; CELL PROTECTION; CROHN DISEASE; DIET; ENZYME INHIBITION; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; PATHOGENESIS; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; CROHN DISEASE; DIET; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; NOD2 SIGNALING ADAPTOR PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84917709210     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1981     Document Type: Review

References (77)

1. Cénit MC, Matzaraki V, Tigchelaar EF and Zhernakova A: Rapidly expanding knowledge on the role of the gut microbiome in health and disease. Biochim Biophys Acta. pii: S0925-4439(14)00151-00153, 2014.
2. Taschuk R and Griebel PJ: Commensal microbiome effects on mucosal immune system development in the ruminant gastrointestinal tract. Anim Health Res Rev 13: 129-141, 2012.
3. Nepal S, Navaneethan U, Bennett AE and Shen B: De novo inflammatory bowel disease and its mimics after organ transplantation. Inflamm Bowel Dis 19: 1518-1527, 2013.
4. Cromer WE, Mathis JM, Granger DN, Chaitanya GV and Alexander JS: Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol 17: 578-593, 2011.
5. van Lent AU and D'Haens GR: Management of postoperative recurrence of Crohn's disease. Dig Dis 31: 222-228, 2013.
6. Irié T, Maeda Y, Aida T, Sumitani K, Nagumo M and Tachikawa T: Multiple granulomatous inflammation in the minor salivary glands: a proposed new entity, allergic granulomatous sialadenitis. Pathol Int 54: 850-853, 2004.
7. Blandizzi C, Gionchetti P, Armuzzi A, Caporali R, Chimenti S, Cimaz R, Cimino L, Lapadula G, Lionetti P, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C and Girolomoni G: The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol 27 (Supple 1): S1-S10, 2014.
8. de Boer NKh, Löwenberg M and Hoentjen F: Management of Crohn's disease in poor responders to adalimumab. Clin Exp Gastroenterol 7: 83-92, 2014.
9. Park S, Regmi SC, Park SY, Lee EK, Chang JH, Ku SK, Kim DH and Kim JA: Protective effect of 7-O-succinyl macrolactin A against intestinal inflammation is mediated through PI3-kinase/Akt/mTOR and NF-κB signaling pathways. Eur J Pharmacol 735: 184-192, 2014.
10. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M and Thomas G: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603, 2001.
11. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G and Cho JH: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603-606, 2001.
12. Eckmann L and Karin M: NOD2 and Crohn's disease: loss or gain of function? Immunity 22: 661-667, 2005.
13. Tsai WH, Huang DY, Yu YH, Chen CY and Lin WW: Dual roles of NOD2 in TLR4-mediated signal transduction and -induced inflammatory gene expression in macrophages. Cell Microbiol 13: 717-730, 2011.
14. Zhao L, Lee JY and Hwang DH: The phosphatidylinositol 3-kinase/Akt pathway negatively regulates Nod2-mediated NF-kappaB pathway. Biochem Pharmacol 75: 1515-1525, 2008.
15. Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, Núñez G and Inohara N: A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J 27: 373-383, 2008.
16. Nomura F, Kawai T, Nakanishi K and Akira S: NF-kappaB activation through IKK-i-dependent I-TRAF/TANK phosphorylation. Genes Cells 5: 191-202, 2000.
17. Terra X, Palozza P, Fernandez-Larrea J, Ardevol A, Blade C, Pujadas G, Salvado J, Arola L and Blay MT: Procyanidin dimer B1 and trimer C1 impair inflammatory response signalling in human monocytes. Free Radic Res 45: 611-619, 2011.
18. Nakanishi A, Wada Y, Kitagishi Y and Matsuda S: Link between PI3K/AKT/PTEN pathway and NOX protein in diseases. Aging Dis 5: 203-211, 2014.
19. Korbecki J, Baranowska-Bosiacka I, Gutowska I and Chlubek D: The effect of reactive oxygen species on the synthesis of prostanoids from arachidonic acid. J Physiol Pharmacol 64: 409-421, 2013.
20. Tamrakar AK, Schertzer JD, Chiu TT, Foley KP, Bilan PJ, Philpott DJ and Klip A: NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance. Endocrinology 151: 5624-5637, 2010.
21. Hales EC, Taub JW and Matherly LH: New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal 26: 149-161, 2014.
22. Johnson SE, Shah N, Bajer AA and LeBien TW: IL-7 activates the phosphatidylinositol 3-kinase/AKT pathway in normal human thymocytes but not normal human B cell precursors. J Immunol 180: 8109-8117, 2008.
23. Okumura N, Yoshida H, Kitagishi Y, Murakami M, Nishimura Y and Matsuda S: PI3K/AKT/PTEN signaling as a molecular target in leukemia angiogenesis. Adv Hematol 2012: 843085, 2012.
24. Theodoropoulou M and Stalla GK: Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34: 228-252, 2013.
25. Liao XH, Buggey J and Kimmel AR: Chemotactic activation of Dictyostelium AGC-family kinases AKT and PKBR1 requires separate but coordinated functions of PDK1 and TORC2. J Cell Sci 123: 983-992, 2010.
26. Kirkegaard T, Witton CJ, Edwards J, et al: Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH. Histopathology 56: 203-211, 2010.
27. Robertson GP: Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev 24: 273-285, 2005.
28. Hodgkinson CP, Sale EM and Sale GJ: Characterization of PDK2 activity against protein kinase B gamma. Biochemistry 41: 10351-10359, 2002.
29. Bartolomé A, Guillén C and Benito M: Role of the TSC1-TSC2 complex in the integration of insulin and glucose signaling involved in pancreatic beta-cell proliferation. Endocrinology 151: 3084-3094, 2010.
30. Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD and Pearson RB: Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors 25: 209-226, 2007.
31. Brand C, Cipok M, Attali V, Bak A and Sampson SR: Protein kinase Cdelta participates in insulin-induced activation of PKB via PDK1. Biochem Biophys Res Commun 349: 954-962, 2006.
32. Kim YM, Seo YH, Park CB, Yoon SH and Yoon G: Roles of GSK3 in metabolic shift toward abnormal anabolism in cell senescence. Ann N Y Acad Sci 1201: 65-71, 2010.
33. Downes CP, Perera N, Ross S and Leslie NR: Substrate specificity and acute regulation of the tumour suppressor phosphatase, PTEN. Biochem Soc Symp: 69-80, 2007.
34. Kong D and Yamori T: Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem 16: 2839-2854, 2009.
35. Chen Y, Wang SM, Wu JC and Huang SH: Effects of PPARgamma agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line. J Cell Biochem 98: 1021-1035, 2006.
36. Leslie NR, Batty IH, Maccario H, Davidson L and Downes CP: Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene 27: 5464-5476, 2008.
37. Sheppard K, Kinross KM, Solomon B, Pearson RB and Phillips WA: Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog 17: 69-95, 2012.
38. Choi BH, Kim CG, Lim Y, Shin SY and Lee YH: Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett 259: 111-118, 2008.
39. Li L, Wei XH, Pan YP, Li HC, Yang H, He QH, Pang Y, Shan Y, Xiong FX, Shao GZ and Zhou RL: LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 29: 5785-5795, 2010.
40. Wu XF, Xu R, Ouyang ZJ, Qian C, Shen Y, Wu XD, Gu YH, Xu Q and Sun Y: Beauvericin ameliorates experimental colitis by inhibiting activated T cells via downregulation of the PI3K/Akt signaling pathway. PLoS One 8: e83013, 2013.
41. Husain N, Tokoro K, Popov JM, Naides SJ, Kwasny MJ and Buchman AL: Neopterin concentration as an index of disease activity in Crohn's disease and ulcerative colitis. J Clin Gastroenterol 47: 246-251, 2013.
42. Das A, Xi L and Kukreja RC: Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 283: 29572-29585, 2008.
43. Molz S, Dal-Cim T, Budni J, Martín-de-Saavedra MD, Egea J, Romero A, del Barrio L, Rodrigues AL, López MG and Tasca CI: Neuroprotective effect of guanosine against glutamate-induced cell death in rat hippocampal slices is mediated by the phosphatidylinositol-3 kinase/Akt/glycogen synthase kinase 3β pathway activation and inducible nitric oxide synthase inhibition. J Neurosci Res 89: 1400-1408, 2011.
44. Imai Y, Yamagishi H, Ono Y and Ueda Y: Versatile inhibitory effects of the flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette transporters that characterize stem cells. Clin Transl Med 1: 24, 2012.
45. Chanoit G, Lee S, Xi J, Zhu M, McIntosh RA, Mueller RA, Norfleet EA and Xu Z: Exogenous zinc protects cardiac cells from reperfusion injury by targeting mitochondrial permeability transition pore through inactivation of glycogen synthase kinase-3beta. Am J Physiol Heart Circ Physiol 295: H1227-H1233, 2008.
46. Jacot JL and Sherris D: Potential therapeutic roles for inhibition of the PI3K/AKT/mTOR pathway in the pathophysiology of diabetic retinopathy. J Ophthalmol 2011: 589813, 2011.
47. Gross ER, Peart JN, Hsu AK, Auchampach JA and Gross GJ: Extending the cardioprotective window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway. Am J Physiol Heart Circ Physiol 288: H2744-H2749, 2005.
48. Burke JP, Cunningham MF, Sweeney C, Docherty NG and O'Connell PR: N-cadherin is overexpressed in Crohn's stricture fibroblasts and promotes intestinal fibroblast migration. Inflamm Bowel Dis 17: 1665-1673, 2011.
49. Kuehn HS, Swindle EJ, Kim MS, Beaven MA, Metcalfe DD and Gilfillan AM: The phosphoinositide 3-kinase-dependent activation of Btk is required for optimal eicosanoid production and generation of reactive oxygen species in antigen-stimulated mast cells. J Immunol 181: 7706-7712, 2008.
50. Lee SB, Cho ES, Yang HS, Kim H and Um HD: Serum withdrawal kills U937 cells by inducing a positive mutual interaction between reactive oxygen species and phosphoinositide 3-kinase. Cell Signal 17: 197-204, 2005.
51. Huang S: A new clue to explain resistance to mTOR inhibitors. Cell Cycle 11: 844, 2012.
52. Alvarado Y, Mita MM, Vemulapalli S, Mahalingam D and Mita AC: Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. Target Oncol 6: 69-94, 2011.
53. Dibble CC and Manning BD: Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol 15: 555-564, 2013.
54. Guo Y and Kwiatkowski DJ: Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis. Mol Cancer Res 11: 467-473, 2013.
55. Massey DC, Bredin F and Parkes M: Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 57: 1294-1296, 2008.
56. Yin H, Li X, Zhang B, Liu T, Yuan B, Ni Q, Hu S and Gu H: Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis. Immunology 139: 494-502, 2013.
57. Albiges L, Chamming's F, Duclos B, Stern M, Motzer RJ, Ravaud A and Camus P: Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 23: 1943-1953, 2012.
58. Waters SM, Coyne GS, Kenny DA and Morris DG: Effect of dietary n-3 polyunsaturated fatty acids on transcription factor regulation in the bovine endometrium. Mol Biol Rep 41: 2745-2755, 2014.
59. Ghosh S, DeCoffe D, Brown K, Rajendiran E, Estaki M, Dai C, Yip A and Gibson DL: Fish oil attenuates omega-6 polyunsaturated fatty acid-induced dysbiosis and infectious colitis but impairs LPS dephosphorylation activity causing sepsis. PLoS One 8: e55468, 2013.
60. Tyagi A, Kumar U, Reddy S, Santosh VS, Mohammed SB, Ehtesham NZ and Ibrahim A: Attenuation of colonic inflammation by partial replacement of dietary linoleic acid with α-linolenic acid in a rat model of inflammatory bowel disease. Br J Nutr 108: 1612-1622, 2012.
61. Zhang Z, Zhang C, Wang H, Zhao J, Liu L, Lee J, He Y and Zheng Q: n-3 polyunsaturated fatty acids prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Int J Cardiol 153: 14-20, 2011.
62. Nauroth JM, Liu YC, Van Elswyk M, Bell R, Hall EB, Chung G and Arterburn LM: Docosahexaenoic acid (DHA) and docosapentaenoic acid (DPAn-6) algal oils reduce inflammatory mediators in human peripheral mononuclear cells in vitro and paw edema in vivo. Lipids 45: 375-384, 2010.
63. Bassaganya-Riera J, Hontecillas R, Horne WT, Sandridge M, Herfarth HH, Bloomfeld R and Isaacs KL: Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn's disease. Clin Nutr 31: 721-727, 2012.
64. Gravaghi C, La Perle KM, Ogrodwski P, Kang JX, Quimby F, Lipkin M and Lamprecht SA: Cox-2 expression, PGE(2) and cytokines production are inhibited by endogenously synthesized n-3 PUFAs in inflamed colon of fat-1 mice. J Nutr Biochem 22: 360-365, 2011.
65. Liu HQ, Qiu Y, Mu Y, Zhang XJ, Liu L, Hou XH, Zhang L, Xu XN, Ji AL, Cao R, Yang RH and Wang F: A high ratio of dietary n-3/n-6 polyunsaturated fatty acids improves obesity-linked inflammation and insulin resistance through suppressing activation of TLR4 in SD rats. Nutr Res 33: 849-858, 2013.
66. Lee JY, Ye J, Gao Z, Youn HS, Lee WH, Zhao L, Sizemore N and Hwang DH: Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem 278: 37041-37051, 2003.
67. Aggarwal BB, Gupta SC and Sung B: Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol 169: 1672-1692, 2013.
68. Song Y, Ge W, Cai H and Zhang H: Curcumin protects mice from coxsackievirus B3-induced myocarditis by inhibiting the phosphatidylinositol 3 kinase/Akt/nuclear factor-κB pathway. J Cardiovasc Pharmacol Ther 18: 560-569, 2013.
69. Fontani F, Marcucci T, Picariello L, Tonelli F, Vincenzini MT and Iantomasi T: Redox regulation of MMP-3/TIMP-1 ratio in intestinal myofibroblasts: effect of N-acetylcysteine and curcumin. Exp Cell Res 323: 77-86, 2014.
70. Krebs S, Omer TN and Omer B: Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease-a controlled clinical trial. Phytomedicine 17: 305-309, 2010.
71. Omer B, Krebs S, Omer H and Noor TO: Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Phytomedicine 14: 87-95, 2007.
72. Son JE, Lee E, Seo SG, Lee J, Kim JE, Kim J, Lee KW and Lee HJ: Eupatilin, a major flavonoid of Artemisia, attenuates aortic smooth muscle cell proliferation and migration by inhibiting PI3K, MKK3/6, and MKK4 activities. Planta Med 79: 1009-1016, 2013.
73. Yo YT, Shieh GS, Hsu KF, Wu CL and Shiau AL: Licorice and licochalcone-A induce autophagy in LNCaP prostate cancer cells by suppression of Bcl-2 expression and the mTOR pathway. J Agric Food Chem 57: 8266-8273, 2009.
74. Yang JY, Della-Fera MA, Rayalam S and Baile CA: Enhanced effects of xanthohumol plus honokiol on apoptosis in 3T3-L1 adipocytes. Obesity (Silver Spring) 16: 1232-1238, 2008.
75. Liu H, Zang C, Emde A, et al: Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. Eur J Pharmacol 591: 43-51, 2008.
76. Roy S, Yu Y, Padhye SB, Sarkar FH and Majumdar AP: Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21. PLoS One 8: e68543, 2013.
77. Yoshida H, Okumura N, Kitagishi Y, Nishimura Y and Matsuda S: Ethanol extract of rosemary repressed PTEN expression in K562 culture cells. Int J Appl Biol Pharm Technol 2: 316-322, 2011.